Karyopharm Net Receivables from 2010 to 2024
| KPTI Stock | USD 1.03 0.07 6.36% |
Net Receivables | First Reported 2010-12-31 | Previous Quarter 27 M | Current Value 25.8 M | Quarterly Volatility 11.5 M |
Check Karyopharm Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Karyopharm main balance sheet or income statement drivers, such as Depreciation And Amortization of 503.5 K, Interest Expense of 25 M or Selling General Administrative of 67.5 M, as well as many exotic indicators such as Price To Sales Ratio of 0.64, Dividend Yield of 0.0 or Days Sales Outstanding of 52.74. Karyopharm financial statements analysis is a perfect complement when working with Karyopharm Therapeutics Valuation or Volatility modules.
Karyopharm | Net Receivables |
Latest Karyopharm Therapeutics' Net Receivables Growth Pattern
Below is the plot of the Net Receivables of Karyopharm Therapeutics over the last few years. It is Karyopharm Therapeutics' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Karyopharm Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Receivables | 10 Years Trend |
|
Net Receivables |
| Timeline |
Karyopharm Net Receivables Regression Statistics
| Arithmetic Mean | 14,256,624 | |
| Geometric Mean | 11,539,358 | |
| Coefficient Of Variation | 80.66 | |
| Mean Deviation | 8,709,582 | |
| Median | 7,862,000 | |
| Standard Deviation | 11,499,161 | |
| Sample Variance | 132.2T | |
| Range | 39.2M | |
| R-Value | 0.71 | |
| Mean Square Error | 71T | |
| R-Squared | 0.50 | |
| Significance | 0 | |
| Slope | 1,821,095 | |
| Total Sum of Squares | 1851.2T |
Karyopharm Net Receivables History
About Karyopharm Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Karyopharm Therapeutics income statement, its balance sheet, and the statement of cash flows. Karyopharm Therapeutics investors use historical funamental indicators, such as Karyopharm Therapeutics's Net Receivables, to determine how well the company is positioned to perform in the future. Although Karyopharm Therapeutics investors may use each financial statement separately, they are all related. The changes in Karyopharm Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Karyopharm Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Karyopharm Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Karyopharm Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Receivables | 27 M | 25.8 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Karyopharm Therapeutics Correlation against competitors. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Karyopharm Stock analysis
When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Karyopharm Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.25) | Revenue Per Share 1.279 | Quarterly Revenue Growth 0.005 | Return On Assets (0.27) | Return On Equity (8.91) |
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.